Feature | Ventricular Assist Devices (VAD) | July 15, 2015

Thoratec Receives CE Mark Approval For HeartMate PHP

Company will begin measured rollout of percutaneous pump with catheter-based hemodynamic support through 2015 and 2016

Thoratec, HeartMate PHP. CE Mark approval, SHIELD I

July 15, 2015 - Thoratec announced that the HeartMate PHP (Percutaneous Heart Pump) received CE Mark approval, permitting sale in the European Union and other international countries. Approval was based on data from the first 30 patients enrolled in the HeartMate PHP SHIELD I CE Mark Trial examining use of PHP to support patients undergoing a high-risk percutaneous coronary intervention (PCI) procedure. Data from all 50 patients enrolled in this study will be presented later in 2015.

HeartMate PHP is an acute cardiac assist device designed to uncouple the traditional relationship between size and flow in catheter-based support devices. The proprietary expandable catheter technology of HeartMate PHP is capable of generating average blood flow of 4-5 liters per minute following delivery through a true percutaneous insertion. The device has been designed for hemocompatibility, with typical operating RPMs of 17,000-20,000. "The SHIELD I clinical experience demonstrated both the performance and ease of use of HeartMate PHP, which was able to safely maintain or improve the hemodynamic profile of severely ill patients undergoing complex revascularizations," said Dariusz Dudek, M.D., the SHIELD I principal investigator and physician in chief, Department of Cardiology and Cardiovascular Interventions at the University Hospital in Krakow, Poland.

The HeartMate PHP European launch will include a measured rollout to targeted countries, staged through the balance of 2015 and 2016. Previously issued company guidance for 2015 financial results included the expected impact of revenue and costs associated with HeartMate PHP and the European launch, with internal resources principally focused on the HeartMate PHP U.S. IDE study. The SHIELD II U.S. IDE trial recently received unconditional approval from the U.S. Food and Drug Administration (FDA) and is still expected to begin enrollment during the third quarter.

For more information: www.thoratec.com

Related Content

The Abiomed Impella percutaneous heart pump during a procedure at Henry Ford Hospital.

The Abiomed Impella percutaneous heart pump during a procedure at Henry Ford Hospital.

Podcast | Hemodynamic Support Devices | May 02, 2019
This podcast is a discussion with ...
Illustration showing the venous implantation route and where the inlet and outflow ports are when the Abiomed Impella RP is placed in the right side of the heart. The  Impella RP catheter is used for right heart hemodynamic support.

Illustration showing the venous implantation route and where the inlet and outflow ports are when the Impella RP is placed in the right side of the heart. 

Feature | Hemodynamic Support Devices | March 26, 2019 | Perwaiz Meraj, M.D. FACC and Uma Chandrasekaran, Ph.D.
Right heart failure (RHF) is a syndrome characterized by the inability of the right ventricle (RV) to support optimal
The Abiomed Impella RP had higher than expected mortality in its post approval study, much higher than in its pre-market approval study. The vendor and the FDA believe this might be due to poor patient selection and implanting the device too late to aid the patient.

The Abiomed Impella RP had higher than expected mortality in its post-approval study, much higher than in its pre-market approval study. The vendor and the FDA believe this might be due to poor patient selection and implanting the device too late to aid the patient.

Feature | Hemodynamic Support Devices | February 05, 2019 | Dave Fornell, Editor
The U.S.
Videos | Hemodynamic Support Devices | September 22, 2018
There was a 77 percent increase in survival in cardiogenic shock patients treated using a new protocol in the...
Videos | Hemodynamic Support Devices | August 31, 2018
Behnam Tehrani, M.D., FSCAI, director of the cardiac cath lab, INOVA Heart and Vascular Institute, Fairfax, Va., disc
Overlay Init